Promising Pharmaceutical Stocks To Add to Your Watchlist - June 26th

Eli Lilly and Company, Thermo Fisher Scientific, and Abbott Laboratories are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in the research, development, manufacturing and marketing of prescription drugs, vaccines and related therapies. Investors in these equities gain exposure to the financial performance and growth prospects of firms whose revenues depend on drug approvals, patent lifecycles and regulatory environments. As a sector, pharmaceutical stocks often display volatility tied to clinical trial outcomes, patent expirations and healthcare policy changes. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

NYSE LLY traded up $2.54 during trading on Thursday, hitting $794.84. 1,649,584 shares of the stock traded hands, compared to its average volume of 3,662,367. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a 50-day simple moving average of $782.41 and a 200-day simple moving average of $800.16. The company has a market capitalization of $753.30 billion, a P/E ratio of 64.72, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40.

Read Our Latest Research Report on LLY

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Thermo Fisher Scientific stock traded up $0.23 during mid-day trading on Thursday, reaching $410.88. 1,732,443 shares of the company's stock traded hands, compared to its average volume of 1,951,074. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a market cap of $155.10 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 2.13 and a beta of 0.78. The stock has a 50 day moving average of $410.39 and a two-hundred day moving average of $485.33. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Read Our Latest Research Report on TMO

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of NYSE:ABT traded down $4.17 during trading on Thursday, reaching $133.23. The company's stock had a trading volume of 4,523,014 shares, compared to its average volume of 6,115,073. The firm's 50 day simple moving average is $132.69 and its two-hundred day simple moving average is $127.30. The company has a current ratio of 1.78, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The stock has a market capitalization of $231.81 billion, a PE ratio of 17.30, a price-to-earnings-growth ratio of 2.62 and a beta of 0.73.

Read Our Latest Research Report on ABT